References
- Becker RE, Greig NH, Giacobini E. Why do so many drugs for Alzheimer’s disease fail in development? Time for new methods and new practices? J Alzheimer’s Dis. 2008;15:303–325.
- Giacobini E, Becker RE, Mecocci P. One hundred years after the discovery of Alzheimer’s disease: a turning point for therapy? J Alzheimers Dis. 2007;12:37–52.
- Becker RE, Greig NH. Alzheimer’s disease drug development in 2008 and beyond: problems and opportunities. Curr Alzheimer Res. 2008;5:346–357.
- Becker RE. Lessons from Darwin: 21st century designs for clinical trials. Curr Alzheimer Res. 2007;4:458–467.
- Vandenberghe R, Rinne JO, Boada M, et al. Bapineuzamab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials. Alzheimer’s Res Ther. 2016 ;8(1):18.
- Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:322–333.
- Doody R, Thomas R, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014 Jan 23;370:311–321.
- Siemers ER, Sundell KL, Carlson C, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement. 2016;12(2):110–120.
- Miller G. Alzheimer's research: stopping Alzheimer’s before it starts. Science. 2012 Aug;337:790–792.
- Available from: https://clinicaltrials.gov/ct2/show/NCT01343966?term=ABBY&rank=1
- Available from: https://clinicaltrials.gov/ct2/show/NCT01397578?term=MABT5102A&rank=3
- Bezprozvanny I. The rise and fall of dimebon. Drug News Perspect. 2010;23(8):518–523.
- Scheltens P, Nikolcheva T, Lasser R, et al. Biomarker data from SCarlet RoAD: a global phase 3 study of gantenerumab in patients with prodromal Alzheimer’s disease (Developing Topics Session: Clinical Trial Results [DT-01-02]). Alzheimers Dement. 2015;11(7):P331.
- Lasser R, Ostrowitzki S, Scheltens P, et al. Efficacy and safety of gantenerumab in prodromal Alzheimer’s disease: results from SCarlet RoAD—a global, multicenter trial (Developing Topics Session: Clinical Trial Results [DT-01-03]). Alzheimers Dement. 2015;11(7):P331–P332.
- Coric V, van Dyck CH, Salloway S, et al. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012;69(11):1430–1440.
- Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med. 2013;369:341–350.
- Mullane K, Williams M. Alzheimer’s therapeutics: continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond? Biochem Pharmacol. 2013;85:289–305.
- Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012 ;71(5):362–381.
- Cummings J, Cho W, Ward M, et al. A randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of crenezumab in patients with mild to moderate Alzheimer’s disease. (abstract O4-11-06). Alzheimers Dement. 2014;10(4):275.
- Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012 ;69(2):198–207.
- Connor DJ, Sabbagh MN. Administration and scoring variance on the ADAS-Cog. J Alzheimers Dis. 2008;15:461–464.
- Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease. The Tacrine Collaborative Study Group. N Engl J Med. 1992;29;327(18):1253–1259.
- Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984;141(11):1356–1364.
- Connor DJ, Schafer K. Administration Manual for the Alzheimer’s Disease Assessment Scale. San Diego: Alzheimer’s Disease Cooperative Study; 1998.
- Becker RE, Greig NH. Why so few drugs for Alzheimers disease? Are methods failing drugs? Curr Alzheimer Res. 2010; 7(7):642–651.